Increased awareness has resulted in more women receiving mammograms, the number of breast cancers detected, and the number of women receiving biopsies. Solos Endoscopy believes that as a result of awareness, breast cancers are being detected at an earlier, more treatable stage. Awareness efforts have successfully utilized marketing approaches to reduce the stigma associated with the disease. However, more work needs to be done. As part of the new MammoView Breast Cancer Global Initiative, Solos Endoscopy plans to team up with the various charities and foundations who are promoting “Breast Cancer Awareness” and educate them about the clinical benefits of the MammoView instrument line and breast ductoscopy. The Solos Endoscopy MammoView Breast Endoscopy System can offer women a positive prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView instrument line allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods. “The MammoView Breast Cancer Global Initiative is more than just awareness, it’s about education, and choices for women.October is over; people and businesses nationwide will take down their pink ribbons and pink signs, yet women all over the world will still be battling breast cancer.Solos Endoscopy will continue its efforts to fight breast cancer not just in October but throughout the year,” stated Robert Segersten, President of Solos Endoscopy. Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014. About Solos Endoscopy, Inc.: Solos Endoscopy celebrated its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.Additional information on its FDA approved products is available on the Company’s website at: http://www.solosendoscopy.com . Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules.
Solos Endoscopy Announces The Mammoview(r) Breast Cancer Global Initiative For 2014
